Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) PT at $33.56

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have received a consensus rating of “Hold” from the twenty-eight analysts that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $32.8462.

SRPT has been the topic of several analyst reports. Mizuho raised shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $19.00 to $26.00 in a report on Wednesday, November 5th. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday. Jefferies Financial Group reiterated a “buy” rating and set a $30.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday. Royal Bank Of Canada boosted their target price on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research report on Thursday, January 8th. Finally, Loop Capital set a $25.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $16.09 on Monday. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48. The company has a market capitalization of $1.69 billion, a PE ratio of -1.91, a price-to-earnings-growth ratio of 0.24 and a beta of 0.42. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $107.77. The business has a 50 day simple moving average of $20.08 and a 200 day simple moving average of $20.12.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). The company had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business’s revenue was down 32.7% on a year-over-year basis. During the same quarter last year, the company earned $1.90 earnings per share. On average, sell-side analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the transaction, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. This trade represents a 6.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors have recently modified their holdings of SRPT. CWM LLC boosted its position in shares of Sarepta Therapeutics by 4,033.3% during the third quarter. CWM LLC now owns 72,705 shares of the biotechnology company’s stock worth $1,401,000 after purchasing an additional 70,946 shares in the last quarter. Aberdeen Group plc increased its position in shares of Sarepta Therapeutics by 59.6% in the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock valued at $38,208,000 after buying an additional 740,360 shares in the last quarter. 683 Capital Management LLC raised its stake in Sarepta Therapeutics by 309.1% during the 2nd quarter. 683 Capital Management LLC now owns 675,000 shares of the biotechnology company’s stock worth $11,542,000 after buying an additional 510,000 shares during the period. State of New Jersey Common Pension Fund D lifted its holdings in Sarepta Therapeutics by 59.9% during the second quarter. State of New Jersey Common Pension Fund D now owns 48,555 shares of the biotechnology company’s stock worth $830,000 after acquiring an additional 18,190 shares in the last quarter. Finally, Edgestream Partners L.P. grew its stake in Sarepta Therapeutics by 870.3% in the second quarter. Edgestream Partners L.P. now owns 82,979 shares of the biotechnology company’s stock valued at $1,419,000 after acquiring an additional 74,427 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.